Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Clear language.

Finley GA.

CMAJ. 2009 Jun 23;180(13):1330. doi: 10.1503/cmaj.1090026. No abstract available.

2.

Clear language.

Arya SC, Agarwal N.

CMAJ. 2009 Jun 23;180(13):1330. doi: 10.1503/cmaj.1090030. No abstract available.

3.

[A plea for clear language on vaccine safety].

MacDonald N, Picard A.

CMAJ. 2009 Mar 31;180(7):E2-3, 697-8. doi: 10.1503/cmaj.090409. English, French. No abstract available.

4.

Testimonials for vaccine-preventable illnesses.

Woelk C.

CMAJ. 2008 Nov 18;179(11):1175. doi: 10.1503/cmaj.1080114. No abstract available.

5.

Fighting for the reputation of vaccines: lessons from American politics.

Parikh RK.

Pediatrics. 2008 Mar;121(3):621-2. doi: 10.1542/peds.2007-3235. No abstract available.

PMID:
18310212
6.

Editors' introduction: Vaccine safety throughout the product life cycle.

Salmon DA, Pavia A, Gellin B.

Pediatrics. 2011 May;127 Suppl 1:S1-4. doi: 10.1542/peds.2010-1722U. Epub 2011 Apr 18. No abstract available.

PMID:
21502245
7.

Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.

Niu MT, Ball R, Woo EJ, Burwen DR, Knippen M, Braun MM; VAERS Working Group..

Vaccine. 2009 Jan 7;27(2):290-7. doi: 10.1016/j.vaccine.2008.10.044. Epub 2008 Nov 6.

PMID:
18992783
8.

Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.

[No authors listed]

Vaccine. 2013 Dec 30;31 Suppl 10:K1. doi: 10.1016/j.vaccine.2013.10.087. No abstract available.

PMID:
24331068
9.
10.

[Vaccines' adverse events: questions and answers brought by InfoVac].

Cohen R, Siegrist CA.

Arch Pediatr. 2006 Jun;13(6):650-2. Epub 2006 May 11. French. No abstract available.

PMID:
16690277
11.

10-year national vaccine plan aims to harness new technology, enhance safety.

Kuehn BM.

JAMA. 2011 Apr 13;305(14):1399-400. doi: 10.1001/jama.2011.435. No abstract available.

PMID:
21486967
12.

[Hazards in the prevention of disease as illustrated on the example of vaccination].

Gärtner H.

Strahlenschutz Forsch Prax. 1976;16:200-3. German. No abstract available.

PMID:
1006700
13.

Vaccines: the conflict between efficacy and public concerns--part 1.

Molinari JA.

Compend Contin Educ Dent. 2004 Feb;25(2):112, 114, 116. No abstract available.

PMID:
15645870
14.

Dr. Jekyll or Mr. Hyde? (How) the Internet influences vaccination decisions: recent evidence and tentative guidelines for online vaccine communication.

Betsch C, Sachse K.

Vaccine. 2012 May 28;30(25):3723-6. doi: 10.1016/j.vaccine.2012.03.078. Epub 2012 Mar 31. No abstract available.

PMID:
22472790
15.

Safety and efficacy of vaccines.

Bartlett BL, Tyring SK.

Dermatol Ther. 2009 Mar-Apr;22(2):97-103. doi: 10.1111/j.1529-8019.2009.01222.x. Review.

PMID:
19335721
16.

Vaccine safety issues: introduction.

Chen RT.

Semin Pediatr Infect Dis. 2003 Jul;14(3):187. No abstract available.

PMID:
12913828
17.

[Vaccinations in adults. Fill in the gaps!].

Stiefelhagen P.

MMW Fortschr Med. 2014 Apr 30;156(8):24. German. No abstract available.

PMID:
24851432
18.

Which pharmacovigilance for vaccines?

Le Louët H, Loupi E, Haramburu F; Round Table No 3, Giens XXII..

Therapie. 2007 May-Jun;62(3):241-7. Epub 2007 Sep 6. Review. English, French.

19.

[Epidemiologic surveillance in health programs].

Bolumar F.

Rev Sanid Hig Publica (Madr). 1981 May-Jun;55(5-6):607-14. Spanish. No abstract available.

PMID:
7348408
20.

Policy statement--recommendations for the prevention and treatment of influenza in children, 2009 -2010.

Committee on Infectious Diseases..

Pediatrics. 2009 Oct;124(4):1216-26. doi: 10.1542/peds.2009-1806. Epub 2009 Sep 7.

PMID:
19736264

Supplemental Content

Support Center